UC Berkeley researchers say large language models have gained "metalinguistic ability," a hallmark of human language and ...

Morgan Stanley has lowered its price target on Recursion Pharmaceuticals (NASDAQ:RXRX) to $5 from $8, while maintaining an Equal Weight rating on the stock.

Comparing Recursion Pharmaceuticals's Short Interest Against Its Peers Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing.

Recursion, Exscientia, and AI drug discovery’s moment of truth Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger.

Recursion Pharma has agreed to merge with rival AI-powered drug discovery firm Exscientia in an all-stock deal valued at $688 million ...

Read about Recursion Pharmaceuticals Inc Class A (RXRX:XNAS) stock and today's latest news and financial updates.

Review which funds and institutions currently hold Recursion Pharmaceuticals Inc Class A (RXRX:XNAS) stock for ownership information.

View the most recent data and latest information on option chains for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.

Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock quote, history, news and other vital information to help you with your stock trading and investing.